-transparent.png){kind=logo}
Treatment of membranous nephropathy and the nephrotic syndrome with 2 mg/kg/day of indomethacin resulted in prompt and sustained reduction in urinary protein excretion and the loss of edema fluid, which allowed the withdrawal of diuretic therapy and liberalization of salt intake. The reduction in proteinuria was paralleled by a decrease in urinary prostaglandin E (PGE) and F (PGF) levels. Plasma PGE and PGF levels did not change appreciably. Withdrawal of indomethacin therapy resulted in an increase in urinary protein and urinary PGE excretion. Reinstitution of therapy resulted in reductions in both values. Indomethacin may provide a useful means of reducing proteinuria and controlling edema in some patients with the nephrotic syndrome.
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
May 1987,
Annals of internal medicine,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
January 1978,
Nephron,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
January 1967,
Marseille medical,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
February 1988,
JPMA. The Journal of the Pakistan Medical Association,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
August 1971,
Revista clinica espanola,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
July 1978,
The Journal of pediatrics,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
September 1979,
Kidney international,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
January 1975,
Minerva nefrologica,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
January 1976,
Acta medica Scandinavica,
I H Shehadeh, and
L M Demers, and
A B Abt, and
A C Schoolwerth
January 1995,
The Journal of pediatrics,
